User profiles for Stephen Liu
 | Stephen V. LiuGeorgetown University Verified email at gunet.georgetown.edu Cited by 14245 |
[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
…, T Mok, S Lam, DS Shames, J Liu… - … England Journal of …, 2018 - Mass Medical Soc
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …
1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of …
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
…, YK Chae, M Barve, I Garrido-Laguna, SV Liu… - The Lancet …, 2020 - thelancet.com
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide …
SV Liu, M Reck, AS Mansfield, T Mok… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579 ), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012
…, M Stanley, SM Guilfoyle, K Sweet, S Liu… - Clinical infectious …, 2014 - academic.oup.com
Acute hepatitis C has increased in the United States from 2006 to 2012 among young
nonurban persons in or nearby Appalachia. Prescription opioids are frequently abused at an …
nonurban persons in or nearby Appalachia. Prescription opioids are frequently abused at an …
[HTML][HTML] COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Background Early reports on patients with cancer and COVID-19 have suggested a high
mortality rate compared with the general population. Patients with thoracic malignancies are …
mortality rate compared with the general population. Patients with thoracic malignancies are …
A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism …
…, K Natarajan, J Rundback, IR Sadiq, SK Liu… - Cardiovascular …, 2015 - jacc.org
Objectives This study conducted a prospective, single-arm, multicenter trial to evaluate the
safety and efficacy of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis, using the …
safety and efficacy of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis, using the …
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and …
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
…, BC Cho, SM Gadgeel, M Thomas, SV Liu… - The lancet …, 2021 - thelancet.com
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, …
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, …
[HTML][HTML] Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study
…, TY Seiwert, DG Pfister, F Worden, SV Liu… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose There are no approved treatments for recurrent/metastatic head and neck squamous
cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-…
cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-…
Collagen in Tendon, Ligament, and Bone Healing: A Current Review.
SH Liu, RS Yang, R Al-Shaikh… - Clinical Orthopaedics and …, 1995 - journals.lww.com
Cells that produce a particular type of collagen under normal physiologic circumstances can
be induced by certain local triggers to change the amount and type of collagen synthesized. …
be induced by certain local triggers to change the amount and type of collagen synthesized. …